https://scholars.lib.ntu.edu.tw/handle/123456789/356599
標題: | Statistical assessment of biosimilar products | 作者: | Chow, S.-C. JEN-PEI LIU |
關鍵字: | Bioequivalence; Biosimilarity; Extrapolation; Follow-on biologic | 公開日期: | 2010 | 卷: | 20 | 期: | 1 | 起(迄)頁: | 10-30 | 來源出版物: | Journal of Biopharmaceutical Statistics | 摘要: | Biological products or medicines are therapeutic agents that are produced using a living system or organism. Access to these life-saving biological products is limited because of their expensive costs. Patents on the early biological products will soon expire in the next few years. This allows other biopharmaceutical/biotech companies to manufacture the generic versions of the biological products, which are referred to as follow-on biological products by the U.S. Food and Drug Administration (FDA) or as biosimilar medicinal products by the European Medicine Agency (EMEA) of the European Union (EU). Competition of cost-effective follow-on biological products with equivalent efficacy and safety can cut down the costs and hence increase patients' access to the much-needed biological pharmaceuticals. Unlike for the conventional pharmaceuticals of small molecules, the complexity and heterogeneity of the molecular structure, complicated manufacturing process, different analytical methods, and possibility of severe immunogenicity reactions make evaluation of equivalence (similarity) between the biosimilar products and their corresponding innovator product a great challenge for both the scientific community and regulatory agencies. In this paper, we provide an overview of the current regulatory requirements for approval of biosimilar products. A review of current criteria for evaluation of bioequivalence for the traditional chemical generic products is provided. A detailed description of the differences between the biosimilar and chemical generic products is given with respect to size and structure, immunogenicity, product quality attributed, and manufacturing processes. In addition, statistical considerations including design criteria, fundamental biosimilar assumptions, and statistical methods are proposed. The possibility of using genomic data in evaluation of biosimilar products is also explored. |
URI: | http://www.scopus.com/inward/record.url?eid=2-s2.0-75649146954&partnerID=MN8TOARS http://scholars.lib.ntu.edu.tw/handle/123456789/356599 |
DOI: | 10.1080/10543400903280266 | SDG/關鍵字: | biological product; generic drug; analytic method; bioequivalence; biological activity; cost effectiveness analysis; dissolution; drug approval; drug cost; drug efficacy; drug manufacture; drug safety; drug structure; European Union; food and drug administration; immunogenicity; priority journal; probability; quality control; review; statistical analysis; Animals; Biological Products; Drug Approval; Humans; Models, Statistical; Therapeutic Equivalency; United States; United States Food and Drug Administration |
顯示於: | 農藝學系 |
在 IR 系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。